Please login to the form below

Not currently logged in
Email:
Password:

Xceleron expands US operations

Xceleron has signed a lease on a multimillion dollar facility in the US to expand its reach in the region

UK-based drug development analytical strategies company, Xceleron, has signed a lease on a multimillion dollar facility in the state of Maryland in the US.

The facility will open in November 2007 housing a new accelerator mass spectrometer (AMS) and employing at least 20 people in scientific, commercial and administrative roles.

The move follows the establishment of Xceleron's North American business in 2005 to meet increased demand in what the company cites as a USD 1bn market worldwide for drug delivery analytics.

CEO of Xceleron, Professor Colin Garner, said: "We will invest up to USD 7.5m on the purchase of a new AMS and associated equipment to carry out analysis on pharmaceutical drug candidates. Our new facility will allow us to substantially increase our development capacity to better serve our customers worldwide."

Dr Pradeep Ganguly, director of the Montgomery County Department of Economic Development, welcomed Xceleron's decision to set up its new accelerator mass Spectrometer (AMS) in the US: "Xceleron is a highly innovative life sciences company, with a technology that will greatly advance drug discovery. We are delighted that this UK-based company has decided to expand in Germantown."

23rd July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics